Free Alerts   Login
Health Care › Biological Products, (No Diagnostic Substances)

IKNA Stock Price Correlated With Ikena Oncology Financials

IKNA Stock Price vs. Quarterly
IKNA
Income Statement
Cash Flow
Balance Sheet

IKNA Income Statement

Enable JavaScript and reload
Revenue, Net:
Revenue Per Share:
Cost of Goods & Services Sold:
Gross Profit:
Selling, General & Admin Expense:
Research & Development Expense:
Total Operating Expenses:
Operating Income:
Income Taxes:
Net Income:
Earnings Per Share, Diluted:
Earnings Per Share, Basic:
Shares Outstanding, Basic Avg:
Shares Outstanding, Diluted Avg:
Common Stock Shares Outstanding:

IKNA Cash Flow

Enable JavaScript and reload
Operating Activities Net Income:
Depreciation, Depletion & Amortization:
Change in Accounts Receiveable:
Net Cash from Operations:
Net Cash from Operations Per Share:
Repurchases/Buybacks Common Stock:
Issuance of Long-term Debt:
Cash Dividends Paid:
Net Cash from Financing Activities:
Property, Plant & Equipment Purchases:
Purchases of Businesses, Net of Cash:
Net Cash from Investing Activities:
Net Change in Cash & Equivalents:

IKNA Balance Sheet

Enable JavaScript and reload
Cash and Cash Equivalents:
Short-Term Investments:
Accounts Receivable, Net:
Inventories:
Total Current Assets:
Property, Plant & Equipment, Net:
Total Assets:
Accounts Payable:
Current Portion of Long-Term Debt:
Total Short-Term Liabilities:
Long Term Debt, Non-Current Portion:
Total Long-Term Liabilities:
Total Liabilities:

Major Holders (from 13F filings)

Investment Type
Change
Value (x$1000)
increase or decrease
Atlas Venture Life Science Advisors
5,018,178 sh
 
$9,886
BVF Il
4,769,164 sh
1,600,000 sh
50%
$9,395
-$4,327
FMR
4,184,293 sh
-273,841 sh
-6%
$8,243
-$11,061
Orbimed Advisors
3,539,358 sh
353,192 sh
11%
$6,973
-$6,823
Omega Fund Management
2,249,123 sh
 
$4,431
Blue Owl Capital Holdings
1,953,616 sh
1,953,616 sh
NEW
$3,849
$3,849
Blackrock.
1,858,156 sh
411,961 sh
28%
$3,661
-$2,600
Vanguard Group
1,524,848 sh
171,864 sh
13%
$3,004
-$2,854
Verition Fund Management
1,322,397 sh
-399,292 sh
-23%
$2,605
-$4,850
Artal Group S.A.
999,513 sh
-850,000 sh
-46%
$1,969
-$6,039
Nea Management Company
570,050 sh
388,577 sh
214%
$1,123
$416
Geode Capital Management
529,369 sh
12,153 sh
2%
$1,043
-$1,197
State Street
410,745 sh
13,700 sh
3%
$809
-$910
Laurion Capital Management Lp
372,613 sh
-162,044 sh
-30%
$734
-$1,581
Adage Capital Partners Gp
287,900 sh
-120,000 sh
-29%
$567
-$1,199
Barclays Plc
244,655 sh
38,110 sh
18%
$0
-$1
Northernrp
238,572 sh
40,560 sh
20%
$470
-$388
Vida Ventures Advisors
225,192 sh
 
$444
Anson Funds Management Lp
209,315 sh
209,315 sh
NEW
$412
$412
Citadel Advisors
178,177 sh
-28,560 sh
-14%
$351
-$544
COMPANY PROFILE
Note 1. Organization and Basis of Presentation Ikena Oncology, Inc. (the "Company") is a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. With its robust biomarker and translational approach the Company aims to develop targeted treatments and define patient populations who are most likely to respond to treatment. The Company's current programs are across the Hippo pathway, RAS pathway, and key immune signals in the tumor-microenvironment (TME), with approaches to targeting both cancer driving targets and mechanisms of resistance to targeted therapies. The Company's focus on patient-driven development is platform and process agnostic, allowing it to research both known and novel targets, with a shared guiding principle of aiming to address the unmet needs of biomarker-defined patient populations. Since the Company commenced operations in 2016, it has advanced multiple product candidates into clinical development. In addition, the Company has a robust pipeline of discovery-stage targeted oncology programs. Basis of Presentation: The Company’s condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the ASC and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). The accompanying condensed consolidated financial statements and footnotes to the financial statements have been prepared on the same basis as the most recently audited annual financial statements and, in the opinion of management, reflect all normal recurring adjustments necessary for the fair presentation of the Company’s financial position as of March 31, 2022 and the results of its operations and its cash flows for the three months ended March 31, 2022. The results for the three months ended March 31, 2022 are not necessarily indicative of results to be expected for the year ending December 31, 2022, any other interim periods, or any future year or period. These condensed consolidated financial statements should be read in conjunction with, our audited consolidated financial statements for the year ended December 31, 2021, which were included in our Annual Report on Form 10-K that was filed with the Securities and Exchange Commission ("SEC") on March 17, 2022.

Free historical financial statements for Ikena Oncology Inc.. See how revenue, income, cash flow, and balance sheet financials have changed over 12 quarters since 2021. Compare with IKNA stock chart to see long term trends.

Data imported from Ikena Oncology Inc. SEC filings. Check original filings before making any investment decision.